Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vilobelimab - InflaRx

Next Previous
Drug Profile

Vilobelimab - InflaRx

Alternative Names: CaC-P29; Gohibic; IFX-1; Vilobelimab-InflaRx

Latest Information Update: 05 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InflaRx
  • Class Anti-infectives; Anti-inflammatories; Antineoplastics; Antivirals; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pyoderma gangrenosum
  • New Molecular Entity Yes
  • Available For Licensing Yes - Adult respiratory distress syndrome

Highest Development Phases

  • Registered COVID-19 pneumonia
  • Phase III Pyoderma gangrenosum
  • Phase II Adult respiratory distress syndrome; Hidradenitis suppurativa
  • Suspended Granulomatosis with polyangiitis; Microscopic polyangiitis
  • No development reported Inflammation
  • Discontinued Sepsis; Squamous cell cancer; Systemic inflammatory response syndrome

Most Recent Events

  • 30 Dec 2025 InflaRx announces intention to conduct a meeting with FDA for Pyoderma gangrenosum
  • 30 Dec 2025 Adverse events and efficacy data from a phase-III trial in Pyoderma gangrenosum released by InflaRx
  • 11 Jul 2025 InflaRx terminates phase-III trial in Pyoderma gangrenosum in USA, France, Beligium, Germany, Hungary, Italy, Poland, Spain, Switzerland and Australia(IV) due to futility (NCT05964413)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top